BACKGROUND: Several studies have reported that peripheral levels of copper and ceruloplasmin (CP) can differentiate patients with Alzheimer's disease (AD) from non-AD cases. The aim of this study was to determine the diagnostic value of serum copper, CP, and non-CP copper levels in a large cohort of AD subjects. METHODS: Serum copper and CP concentrations were measured at baseline and at 18-months in participants from the Australian Imaging Biomarkers and Lifestyle Study of Ageing. Cross-sectional and longitudinal analyses were conducted using both univariate and multivariate testing adjusting for age, gender, total protein, and ApoE ε4 genotype status. RESULTS: There was no significant difference in levels of serum copper or CP between the AD and healthy control groups, however, we identified a near-significant decrease in non-CP copper in the mild cognitive impairment and AD groups at baseline (p = 0.02) that was significant at 18-months (p = 0.003). CONCLUSION: Our results suggest that there may be decreased non-CP copper levels in mild cognitive impairment and AD, which is consistent with diminished copper-dependent biochemical activities described in AD.
BACKGROUND: Several studies have reported that peripheral levels of copper and ceruloplasmin (CP) can differentiate patients with Alzheimer's disease (AD) from non-AD cases. The aim of this study was to determine the diagnostic value of serum copper, CP, and non-CPcopper levels in a large cohort of AD subjects. METHODS: Serum copper and CP concentrations were measured at baseline and at 18-months in participants from the Australian Imaging Biomarkers and Lifestyle Study of Ageing. Cross-sectional and longitudinal analyses were conducted using both univariate and multivariate testing adjusting for age, gender, total protein, and ApoE ε4 genotype status. RESULTS: There was no significant difference in levels of serum copper or CP between the AD and healthy control groups, however, we identified a near-significant decrease in non-CPcopper in the mild cognitive impairment and AD groups at baseline (p = 0.02) that was significant at 18-months (p = 0.003). CONCLUSION: Our results suggest that there may be decreased non-CPcopper levels in mild cognitive impairment and AD, which is consistent with diminished copper-dependent biochemical activities described in AD.
Authors: Sian Genoud; Blaine R Roberts; Adam P Gunn; Glenda M Halliday; Simon J G Lewis; Helen J Ball; Dominic J Hare; Kay L Double Journal: Metallomics Date: 2017-10-18 Impact factor: 4.526
Authors: Alan Rembach; Francesco C Stingo; Christine Peterson; Marina Vannucci; Kim-Anh Do; William J Wilson; S Lance Macaulay; Timothy M Ryan; Ralph N Martins; David Ames; Colin L Masters; James D Doecke Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Emma Lawrence; Carolin Vegvari; Alison Ower; Christoforos Hadjichrysanthou; Frank De Wolf; Roy M Anderson Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Xin Yi Choo; Jeffrey R Liddell; Mikko T Huuskonen; Alexandra Grubman; Diane Moujalled; Jessica Roberts; Kai Kysenius; Lauren Patten; Hazel Quek; Lotta E Oikari; Clare Duncan; Simon A James; Lachlan E McInnes; David J Hayne; Paul S Donnelly; Eveliina Pollari; Suvi Vähätalo; Katarína Lejavová; Mikko I Kettunen; Tarja Malm; Jari Koistinaho; Anthony R White; Katja M Kanninen Journal: Front Neurosci Date: 2018-09-24 Impact factor: 4.677
Authors: Alan Rembach; Dominic J Hare; Monica Lind; Christopher J Fowler; Robert A Cherny; Catriona McLean; Ashley I Bush; Colin L Masters; Blaine R Roberts Journal: Int J Alzheimers Dis Date: 2013-10-21
Authors: Julia Muenchhoff; Anne Poljak; Anbupalam Thalamuthu; Veer B Gupta; Pratishtha Chatterjee; Mark Raftery; Colin L Masters; John C Morris; Randall J Bateman; Anne M Fagan; Ralph N Martins; Perminder S Sachdev Journal: Sci Rep Date: 2016-07-06 Impact factor: 4.379